SparingVision

SparingVision is a French biotech innovator leading a paradigm shift in ocular disease treatment through mutation-independent genomic medicines. Its lead asset, SPVN06, is a neuroprotective gene therapy for IRDs currently in clinical trials, with a second program, SPVN20/30, in development. The company leverages AAV-based gene therapy to restore physiological mechanisms in the retina, targeting large patient populations underserved by single-gene approaches. Founded in 2016, SparingVision combines deep ophthalmic research expertise with a clinical-stage pipeline to address significant unmet needs in retinal degeneration.

AAV-based gene therapy platform for mutation-independent treatment of retinal diseases. Delivers genes encoding therapeutic proteins to restore physiological mechanisms in the retina, independent of the patient's specific causative gene mutation.

Competition includes both mutation-specific gene therapy companies (e.g., Spark Therapeutics) for specific IRD subtypes and other companies exploring mutation-agnostic approaches such as neuroprotection, optogenetics, or RNA therapies. The dry AMD/GA space is highly competitive with numerous large pharma and biotech players.